We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-11.18%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.48B
AUM Growth
-$398M
Cap. Flow
+$373M
Cap. Flow %
6.82%
Top 10 Hldgs %
68.73%
Holding
45
New
4
Increased
20
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$185M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$178M
3
ARGX icon
argenx
ARGX
+$84.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$39.5M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$34.3M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$272M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$115M
3
UTHR icon
United Therapeutics
UTHR
+$953K
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$844K
5
NUVL
Nuvalent
NUVL
+$773K

Sector Composition

Rank Sector Weight
1 Healthcare 94.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$32M 0.58%
10,300,000
– –
WHWK
27
Whitehawk Therapeutics
WHWK
$235M
$31M 0.57%
1,829,402
– –
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.4B
$30.5M 0.56%
+1,875,000
New +$30.1M
MRNS
29
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$29.5M 0.54%
3,150,000
-85,000
-3% -$844K
MRSN
30
DELISTED
Mersana Therapeutics
MRSN
$27.1M 0.5%
272,000
– –
RNAM
31
DELISTED
Avidity Biosciences
RNAM
$24M 0.44%
1,300,000
+70,000
+6% +$1.19M
PRAX icon
32
Praxis Precision Medicines
PRAX
$10.1B
$22M 0.4%
143,333
+24,666
+21% +$5.07M
DICE
33
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$20.6M 0.38%
1,075,000
+512,500
+91% +$9.15M
AMRN
34
Amarin Corp
AMRN
$303M
$19.7M 0.36%
300,000
– –
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$2.55B
$16.7M 0.3%
+230,000
New +$16M
NUVL
36
DELISTED
Nuvalent
NUVL
$14.6M 0.27%
1,049,471
-53,200
-5% -$773K
TNGX icon
37
Tango Therapeutics
TNGX
$4.41B
$11.7M 0.21%
1,550,000
– –
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$11.4M 0.21%
1,670,000
– –
IOBT
39
DELISTED
IO Biotech
IOBT
$9.58M 0.17%
2,055,883
– –
ADVM
40
DELISTED
Adverum Biotechnologies
ADVM
$9.11M 0.17%
695,000
– –
AMTI
41
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$7.75M 0.14%
+1,030,000
New +$8.53M
FENC icon
42
Fennec Pharmaceuticals
FENC
$402M
$6.72M 0.12%
1,200,000
– –
GNCA
43
DELISTED
Genocea Biosciences, Inc.
GNCA
$6.36M 0.12%
5,084,184
– –
SRPT icon
44
CALL
Sarepta Therapeutics
SRPT
$1.77B
– –
-300,000
Closed -$2.91M
ARNA
45
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-1,235,000
Closed -$115M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Avoro Capital Advisors held 45 positions worth $5.48B, down 6.8% from $5.88B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors deployed $373M of net new capital in Q1 2022, opening 4 new positions and adding to 20 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,315,000 shares worth $189M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $272M trimmed.

  • Avoro Capital Advisors's largest Q1 2022 buy was Seagen Inc. Common Stock: 1,315,000 shares worth $189M.
  • Avoro Capital Advisors added most to State Street SPDR S&P Biotech ETF in Q1 2022, an estimated $185M increase.
  • Avoro Capital Advisors's biggest Q1 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $272M.
  • Avoro Capital Advisors fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $115M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.48B portfolio in Q1 2022.
  • Avoro Capital Advisors opened 4 new positions and closed 2 in Q1 2022.
  • Avoro Capital Advisors's portfolio value fell 6.8% quarter-over-quarter to $5.48B.

Based on Avoro Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.